AZD-3783, also known as AZ12320927, is a serotonin 5-HT1B receptor antagonist which was under development for the treatment of major depressive disorder and anxiety disorders. It was being developed by AstraZeneca. The drug reached phase 1 clinical trials prior to the discontinuation of its development. It was discontinued following unexpected neurotoxicity findings in animals.
See also AZD-1134 List of investigational antidepressants List of investigational anxiolytics
References